NanoViricides, Inc. (NYSE: NNVC) is a development stage company with a unique nanomedicine technology. The company is developing nanotechnology-based biomimetic anti-viral medicines, that we call “nanoviricides”. Virus-specific nanoviricide drug candidates against five commercially important viral diseases, viz. seasonal and potentially epidemic influenzas and bird flu, HIV/AIDS, cold sores and genital herpes infection, viral eye diseases, as well as dengue viruses, have demonstrated very high levels of effectiveness. SNNLive spoke with Eugene Seymour, MD, MPH, CEO of NanoViricides, Inc. at Singular Research's 9th Annual "Best of the Uncovereds" Conference 2014 in Bel Air, CA.
Dr. Seymour begins with an update on the company and how they are contributing to the efforts against Ebola, “We’re working actively on Ebola now. I don’t want anyone to think that we’re not continuing the process with our Flu side drug moving into toxicology and then into human trials as per schedule, but the Ebola was too important an humanitarian crisis to not get involved in. We did this five years ago, there was a tremendous loss of interest after the last epidemic was over and the research wasn’t far enough along to really show us just exactly what the nature of the virus was and its attachment protein. So using the latest research, we did announce recently that we’re synthesizing a new version – Ebola side 2 and hopefully it’s going to be sent to a high-security BSL for bio-containment center within the next few weeks for small animal and large animal testing.”
NanoViricides has already done ten different viruses, about 6,000 animal tests and are focused on the complicated flu and other illnesses that there have no current treatments. When deciding on which diseases to take on and which of those to focus on first, Nanoviricides looks “at diseases that are most prevalent. Flu – hospitalized patients as many as 500,000 a year in the US and as many as 50,000 deaths. That’s why we’re focusing on the flue and if there’s any way you can treat a person, get them out of the hospital within a very short period of time then you obviate a longer stay in the hospital which is good for the patient and good for the healthcare system. Now many of the diseases that impact children here, adults here, are not virally caused so we only focus on viruses using our platform to rapidly create drugs to destroy viruses.”
Dr. Seymour explains that “the key is the platform. Call me up and you say we have this virus, I get a sample of it, we can create a drug for you pretty quickly.” Nanoviricides has previously done this for the British government and for the Middle East Respiratory Syndrome. For more information, check out their website at www.nanoviricides.com
© 2017 Stock News Now
Supported by Superior Web Solutions